Course "FDA's Software Monsters: Cybersecurity, Interoperability, Mobile Apps and Home Use" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.
Overview:
Software's level of complexity and use is expanding at exponential levels. Likewise, the potential risks to health follow suit. Ransomeware attacks hold your software hostage until you pay hundreds or thousands of dollars. Life supporting and life sustaining healthcare grinds to a halt. Extracting personal healthcare information is another plague that has a huge financial incentive for hackers. Your software is running on thin ice.
The FDA looks at software in one of three ways: Standalone, such as for a mobile app; device-based software used to control a device's performance, or simply electronic records. FDA's risk classification will gradually clarify how it intends to manage the health risks with premarket and postmarket controls. What the FDA did not see was the cancer of cybersecurity attacks, the failure of interoperability, and the explosion in the use of wireless communication and mobile apps.
Inadequate cybersecurity programs and the lack of interoperability for healthcare users pose the greatest threat to any healthcare system. Software exploitations are using more sophisticated approaches and the hackers' programs are readily available on the "dark web."
The increasing sophistication required to protect software programs and have them work with other programs requires progressive software design and software validation considerations. In many instances, validation is limited to the immediate use of the software rather than its environment of use, its performance with other software programs and software hacking. FDA can ask you what you have considered before you take a product to market. Whether your software can survive unscathed is another question. When software causes a problem, fixing the malfunction or "bug" may be more difficult as software becomes more sophisticated, customized by users and placed in a network system. In these kinds of circumstances, it is difficult to decide who is responsible for managing and fixing the software problems, preventing them from recurring. This becomes a major regulatory headache for FDA and generates business-to-business conflicts. When firms are designing and marketing software, they should be mindful of the unknowns that lurk in the future of software regulated as a device by the FDA.
Why you should attend:
For decades, firms have experienced serious problems with software and have been at a loss to make a well-informed follow up. Software problems represent one of the most common root causes for recalls that are associated with deaths and serious injuries beyond what should be necessary to quantify. FDA sees firms revise software only to create more problems rather than solve them. The infusion pump industry is a classic example that drove FDA to implement a new rigorous paradigm for premarket review and performance criteria evaluation.
The growth of the medical software industry outpaces how FDA's regulatory process is designed. How can you anticipate and defend against the malicious remote hacking and shut down of an insulin infusion pump? In some instances, clinicians have weighed the risk of software failure against the benefits of using a device at all. You need to understand and apply the current provisions that NIST has put forth in recent reports FDA will integrate them into its regulatory oversight of cybersecurity management.
Device software is often used in conjunction with other software-based devices, but their interoperability was never anticipated. Can one software program defeat the performance capability or back up safety features of another software program? When interoperability problems surface, which software manufacturer takes the lead to solve the problem and deal with proprietary software issues?
These are the kinds of issues that will be highlighted during the seminar. The issues require careful consideration even though no obvious answer appears at hand.
Topics:
FDA's risk-based regulatory strategy
Cybersecurity
Interoperability
National Institute of Standards and Technology
Voluntary standards and programs
Mobile Apps
Premarket software validation and design requirements
Postmarket Software recalls
Who Will Benefit:
Regulatory Affairs
Quality Assurance
Software Design Engineers
Manufacturing
Complaint Dept.
Hospital Risk Dept.
Own label marketers
Agenda:
Day 1 Schedule
9:00 am - 10:15 am
Lecture 1: FDA authority and regulatory program
Types of Software are devices
Regulatory strategy
Risk classification
Office of the National Coordinator (ONC) for Health Information Protection
Software regulatory applications
FDA Guidance
Premarket submissions
Paradigms: aeronautics
10:15am - 10:30am Break
10:30 am - 12:00 am
Quality System Regulation (QSR)
Design verification and validation
Voluntary standards
Corrective and Prevent Action Plans
Voluntary standards
Recalls:
Service / maintenance / recall.
Implementation strategy
Corrections and Removals reporting
Updates: FDA vs. non-FDA
Predictive analytics
12:00 PM - 1:00 PM Lunch
1:00 PM - 2:30 PM
Lecture 2: Interoperability
Compatibility by design
Hardware
Software
Labeling
Precautions
Instructions for use
Use of Voluntary Standards
2:30 PM - 2:45 PM Break
2:45 PM - 4:15 PM
Proprietary information
Failure management / follow up
User's vs. manufacturer's legal responsibility
System configuration
Customization
Environment of use
Professional
Day 2 Schedule
9:00 am - 10:15 am
Lecture 1: Cybersecurity
Device vulnerabilities: malfunction and failure
Pre-emptive design and evolution
Hackers' malware/virus strategy
10:30 am - 10:45 am Break
10:45 am - 12:00 pm
Post-event management
Corrective and preventive action for software
Disclosure to users
Reports to the FDA waiver
National Institute of Standards and Technology Reports
12:00 PM - 1:00 PM Lunch
1:00 PM - 2:30 PM
Lecture 2: Medical Mobile Applications (mobile apps)
Mobile apps defined as a device
FDA regulatory strategy and guidance
National Institute of Science and Technology Report and Collaboration
Updates (FDA vs. non-FDA updates)
Criteria for corrective and preventive action deemed recalls
Reports of Corrections and Removals
Reports of adverse events
2:30 PM - 2:45 PM Break
2:45 PM - 4:30 PM
Lecture 3: Professional vs. lay use / home use
Labeling: instructions for use and precautions
Environment of use
FDA regulation of accessories
Federal Communications Commission (FCC) regulation
Speaker
Casper Uldriks
ex-FDA Expert and former Associate Center Director of CDRH
Casper (Cap) Uldriks owns Encore Insight LLC, which provides consulting services on FDA Law. He brings over 32 years of experience from the FDA. He specialized in the FDA's medical device program as a field investigator, served as a senior manager in the Office of Compliance and as an Associate Center Director for the Center for Devices and Radiological Health. He developed enforcement actions and participated in the implementation of new statutory requirements. He is recognized as an exceptional and energetic speaker. His comments are candid, straightforward and of practical value. He understands how FDA thinks, operates and where it is headed.
Location: Baltimore, MD Date: August 16th & 17th, 2018 and Time: 9:00 AM to 6:00 PM
Venue: The DoubleTree Baltimore-BWI Airport 890 Elkridge Landing Road - Linthicum, MD 21090
Price:
Price: $1,295.00 (Seminar Fee for One Delegate)
Register for 5 attendees Price: $3,885.00 $6,475.00 You Save: $2,590.00 (40%)*
Register for 10 attendees Price: $7,122.00 $12,950.00 You Save: $5,828.00 (45%)*
Register now and save $200. (Early Bird)
Until July 10, Early Bird Price: $1,295.00 From July 11 to August 14, Regular Price: $1,495.00
Sponsorship Program benefits for seminar
For More Information- https://www.globalcompliancepanel.com/control/sponsorship
Contact us today!
NetZealous LLC DBA GlobalCompliancePanel
Toll free: +1-800-447-9407
Phone: +1-510-584-9661
Website: http://www.globalcompliancepanel.com
Follow us on LinkedIn: https://www.linkedin.com/company/globalcompliancepanelindia/
Like us our Facebook page: https://www.facebook.com/TrainingsAtGlobalCompliancePanel/
Follow us on Twitter: https://twitter.com/GCPanel